LON:VEC Vectura Group (VEC) Share Price, News & Analysis → Bitcoin Rockets To Record High But Buy THIS Instead (From Paradigm Press) (Ad) Free VEC Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range 164.80▼ 164.8052-Week Range N/AVolume203,761 shsAverage Volume3.37 million shsMarket Capitalization£1.01 billionP/E Ratio8.20Dividend Yield23.06%Price TargetN/A Stock AnalysisStock Analysis Get Vectura Group alerts: Email Address Ad Stansberry Research$5,000 Gold?Former Wall Street Banker Reveals Mysterious Gold Leverage As gold continues to soar, this ex-Goldman Sachs VP says DON'T buy bullion or mining stocks. Instead, he's just shared a "gold bank" that uses about $10 of your money to harness the power of two ounces of pure gold (worth about $4,200 right now).Find out how to do right here in this free video. About Vectura Group Stock (LON:VEC)Vectura Group plc engages in the design, development, and supply of pharmaceutical products for the treatment of airways-related diseases worldwide. The company's in-market products include Seebri, Breezhaler and Neohaler, a DPI device and bronchodilator; AirFluSal Forspiro for the treatment of asthma and chronic obstructive pulmonary disease (COPD); Breelib for the treatment of pulmonary arterial hypertension; Relvar Ellipta/Breo Ellipta that is used in treating asthma and COPD; and Incruse Ellipta, Anoro Ellipta, and Trelegy Ellipta for the treatment of COPD. It is also developing VR315 (US) for the treatment of asthma and COPD.In addition, the company offers dry powder inhalers, pressurized metered dose inhalers, and nebulized devices. Vectura Group plc was founded in 1997 and is headquartered in Chippenham, the United Kingdom.Read More Ad Stansberry Research$5,000 Gold?Former Wall Street Banker Reveals Mysterious Gold Leverage As gold continues to soar, this ex-Goldman Sachs VP says DON'T buy bullion or mining stocks. Instead, he's just shared a "gold bank" that uses about $10 of your money to harness the power of two ounces of pure gold (worth about $4,200 right now).Find out how to do right here in this free video. VEC Stock News HeadlinesApril 16, 2024 | finance.yahoo.comWalmart chooses Swisslog ASRS powered by SynQ software to enhance transparency and delivery of quality products in third milk processing facilityFebruary 3, 2024 | finance.yahoo.comGlobal Smart Inhalers Market to Surpass 51.85 Billion by 2030 Driven by Increasing Prevalence of Chronic Respiratory DiseasesMay 2, 2024 | TradeSmith (Ad)The A.I. story nobody is telling you (Read ASAP)There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...January 16, 2024 | finance.yahoo.comPhilip Morris (PM) Poised Well on Pricing, Smoke-Free StrengthOctober 6, 2023 | lse.co.ukVEC.L Regulatory NewsSeptember 20, 2023 | msn.comPhilip Morris (NYSE:PM) Mulls Stake Sale in Pharma UnitSeptember 20, 2023 | msn.comTobacco Giant Philip Morris Rethinks Pharma Dive, Mulls Vectura Stake Sale Amid Challenges: ReportSeptember 20, 2023 | msn.comPhilip Morris evaluates selling stake in pharmaceuticals unit - reportMay 2, 2024 | TradeSmith (Ad)The A.I. story nobody is telling you (Read ASAP)There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...September 4, 2023 | washingtonpost.comNestle’s Lessons From Joining the Dud Deals ClubJuly 24, 2023 | uk.investing.comMonday newspaper round-up: Business energy, Vectura, Rhodes fire, Barbenheimer, interest ratesJuly 23, 2023 | thetimes.co.ukBlow to PMI as top executives quit VecturaJuly 22, 2023 | msn.comCITY WHISPERS: Whiff of change in the air for cannabis firmsJune 10, 2023 | forbes.comMetro GroupJune 1, 2023 | ft.comPMI should forget wellness and focus on smokers who want to quitMay 17, 2023 | marketwatch.comIpratropium Bromide Market Forthcoming Trends and Share Analysis by 2031May 8, 2023 | marketwatch.comLatest "Ipratropium Bromide Market" Size Forecast 2023-2031: New Challenges, Drivers, and RestraintsMay 3, 2023 | marketwatch.com2023-2030 Targeted Drug Delivery System Market Size (Growth and Outlook) includes Latest Development | with [124 Pages]April 30, 2023 | marketwatch.comNebulizers Market is poised to cross USD 1.9 billion by 2032April 25, 2023 | marketwatch.comIpratropium Bromide Market Manufacturing Cost Structure By 2030April 22, 2023 | marketwatch.com2023-2030 Potassium Gluconate Market Size with [96 Pages] includes Market Restraints | New Report by Absolute ReportsApril 3, 2023 | finance.yahoo.comAerami Therapeutics to Host Virtual Investor Day with Leading Experts in Pulmonary Hypertension as AER-901 (Inhaled Imatinib) Advances Toward Phase 2March 28, 2023 | marketwatch.comPolymers Drug Delivery Market Share and Forecast till 2031March 28, 2023 | marketwatch.comIpratropium Bromide Market Share and Forecast till 2028March 28, 2023 | marketwatch.comAsthma and COPD Drugs Market Outlook and Forecast till 2031March 27, 2023 | marketwatch.comOral Drug Delivery Market Growth and Forecast till 2031March 24, 2023 | marketwatch.comMedical Suction Catheters Market Size, Share, Growth | Global Report, 2031See More Headlines Receive VEC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vectura Group and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Drug Manufacturers - Major Sub-IndustryN/A Current SymbolLON:VEC CUSIPN/A CIKN/A Webwww.vectura.com Phone+44-1249-667700FaxN/AEmployees9,200Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E Ratio8.20 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.77 Current Ratio3.59 Quick Ratio3.20 Sales & Book Value Annual Sales£190.60 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow12.48 Book ValueGBX 91.70 per share Price / BookN/AMiscellaneous Outstanding Shares613,892,000Free FloatN/AMarket Cap£1.01 billion OptionableNot Optionable BetaN/A 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. William Downie (Age 54)CEO & Exec. Director Comp: $538.92kMr. Paul Andrew Fry (Age 54)CFO & Exec. Director Comp: $807kMr. Anthony FitzpatrickExec. VP of OperationsDr. Geraldine VenthoyeChief Scientific Officer & Exec. VP of Product Devel.Elizabeth KnowlesVP of Investor RelationsMr. John Murphy (Age 68)Gen. Counsel & Company Sec. David GinivanVP of Corp. CommunicationsMs. Christina OlsenExec. VP of Corp. Strategy & CommunicationsMs. Joanne Hombal (Age 47)Exec. VP of HR Mr. Roger Heerman (Age 48)Exec. VP of Commercial & Bus. Devel. More ExecutivesKey CompetitorsSpire Healthcare GroupLON:SPIGenusLON:GNSOxford Nanopore TechnologiesLON:ONTCareTechLON:CTHEMIS GroupLON:EMISView All Competitors VEC Stock Analysis - Frequently Asked Questions Is Vectura Group a good dividend stock? Vectura Group (LON:VEC) pays an annual dividend of GBX 38 per share and currently has a dividend yield of 23.06%. VEC has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. The dividend payout ratio is 189.05%. Payout ratios above 75% are not desirable because they may not be sustainable. Read our dividend analysis for VEC. What other stocks do shareholders of Vectura Group own? Based on aggregate information from My MarketBeat watchlists, some companies that other Vectura Group investors own include Hikma Pharmaceuticals (HIK), SEB (SKP), BTG (BTG), iRobot (IRBT), Sinclair Pharma (SPH), Sirius Minerals (SXX), Coats Group (COA), Griffin Mining (GFM), HSBC (HSBA) and Inmarsat (ISAT). How do I buy shares of Vectura Group? Shares of VEC stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. This page (LON:VEC) was last updated on 5/2/2024 by MarketBeat.com Staff From Our PartnersBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressUrgent Nvidia WarningAltimetryThe A.I. story nobody is telling you (Read ASAP)TradeSmithThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingTrump just won 2024Porter & CompanyHe Is Giving Away BitcoinCrypto Swap Profits4 Cryptos BETTER than BitcoinTrue Market InsidersThe only AI company you should be looking atBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vectura Group plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.